Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 2;10(11):609.
doi: 10.3390/v10110609.

Clinical Features of Varicella-Zoster Virus Infection

Affiliations
Review

Clinical Features of Varicella-Zoster Virus Infection

Peter G E Kennedy et al. Viruses. .

Abstract

Varicella-zoster virus (VZV) is a pathogenic human herpes virus that causes varicella (chickenpox) as a primary infection, following which it becomes latent in peripheral ganglia. Decades later, the virus may reactivate either spontaneously or after a number of triggering factors to cause herpes zoster (shingles). Varicella and its complications are more severe in the immunosuppressed. The most frequent and important complication of VZV reactivation is postherpetic neuralgia, the cause of which is unknown and for which treatment is usually ineffective. Reactivation of VZV may also cause a wide variety of neurological syndromes, the most significant of which is a vasculitis, which is treated with corticosteroids and the antiviral drug acyclovir. Other VZV reactivation complications include an encephalitis, segmental motor weakness and myelopathy, cranial neuropathies, Guillain⁻Barré syndrome, enteric features, and zoster sine herpete, in which the viral reactivation occurs in the absence of the characteristic dermatomally distributed vesicular rash of herpes zoster. There has also been a recent association of VZV with giant cell arteritis and this interesting finding needs further corroboration. Vaccination is now available for the prevention of both varicella in children and herpes zoster in older individuals.

Keywords: VZV; acyclovir; enteric zoster; herpes zoster; infection; neurology; postherpetic neuralgia; valacyclovir; varicella.

PubMed Disclaimer

Conflict of interest statement

Peter Kennedy declares no conflicts. Anne Gershon receives NIH grant support (R01 DK 93094). She receives laboratory support from Merck & Co., to monitor/identify safety of VZV immunizations using molecular methodology.

Similar articles

Cited by

References

    1. Gershon A.A., Breuer J., Cohen J.I., Cohrs R.J., Gershon M.D., Gilden D., Grose C., Hambleton S., Kennedy P.G.E., Oxman M., et al. Varicella zoster virus infection. Nat. Rev. Dis Prim. 2015;1:15016. doi: 10.1038/nrdp.2015.16. - DOI - PMC - PubMed
    1. Kennedy P.G.E. Varicella-zoster virus latency in human ganglia. Rev. Med. Virol. 2002;12:327–334. doi: 10.1002/rmv.362. - DOI - PubMed
    1. Nagel M.A., Gilden D.H. The protean neurologic manifestations of varicella-zoster virus. Cleve Clin. J. Med. 2007;74:489–504. doi: 10.3949/ccjm.74.7.489. - DOI - PubMed
    1. Burke B.L., Steele R.W., Beard O.W., Wood J.S., Cain T.D., Marmer D.J. Immune responses to varicella-zoster in the aged. Arch. Intern. Med. 1982;142:291–293. doi: 10.1001/archinte.1982.00340150091017. - DOI - PubMed
    1. Berger R., Luescher D., Just M. Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J. Infect. Dis. 1984;149:647. doi: 10.1093/infdis/149.4.647. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources